• Latest

Eisai: Application for Additional Indication of Anti Cancer Agent Lenvima for Unresectable Thymic Carcinoma Submitted in Japan

New Delhi, August  04, 2020:  Eisai Co., Ltd. and MSD K.K. a subsidiary of Merck & Co., Inc., Kenilworth, N.J.,…

• Product News
• Products
• Products (D)

Eisai to Present Data on Oncology Pipeline and Products at ASCO20 Annual Meeting

New Delhi, May 17, 2020: Eisai Co., Ltd. announced today that presentations on a series of abstracts regarding its in-house…

• Product News

Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO 2019 Congress

Tokyo, September 29, 2019: Eisai Co., Ltd. announced today that a series of abstracts will be presented during the European…

• Events

Eisai to Present Data on Oncology Pipeline and Products at 55th Asco Annual Meeting

Tokyo, May 16, 2019: Eisai Co., Ltd. announced today that presentations on a series of abstracts highlighting updates regarding its…

Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Announce U.S. FDA Grants Breakthrough Therapy Designation for LENVIMA

In Combination with KEYTRUDA as Therapy for Previously Treated Patients with Advanced and/or Metastatic non-MSI-H/pMMR Endometrial Carcinoma Tokyo, August 05,…